Stockwatch: The punctuations of life science investment
This article was originally published in Scrip
As investors in the life sciences sector bask in the glow of another significant monthly return, it is clear that not even the Ukrainian crisis can dampen the advance of the biotech sector. There were some tense days last week when virtually all pharmaceutical and biotechnology stocks went down with the market (and those recent biotech IPOs moved down much more than most other stocks), but by the end of the week the bankers touting IPOs and secondary offerings had re-emerged from their bunkers, swapped their tin hats for their toupees and started to barrack investors again.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.